Literature DB >> 25163735

Are patient self-report questionnaires as "scientific" as biomarkers in "treat-to-target" and prognosis in rheumatoid arthritis?

Theodore Pincus, Isabel Castrejón1.   

Abstract

Information from patients traditionally is regarded as "subjective," in contrast to "objective," "scientific" laboratory data. However, patient questionnaire scores for physical function are more significant to predict severe outcomes of rheumatoid arthritis (RA), such as work disability and mortality, than radiographs or laboratory tests. Furthermore, the 3 RA Core Data Set patient self-report measures of physical function, pain, and patient global estimate are as effective as radiographs or laboratory tests to distinguish active from control treatments in clinical trials. A multidimensional health assessment questionnaire (MDHAQ) has been developed in routine clinical care, to be completed by patients in 5-10 minutes and contribute to clinical decisions, in contrast to research questionnaires which may provide extensive information, but often are lengthy, unfeasible for routine care, and not designed to add to clinical care. RAPID3 (routine assessment of patient index data) is an index included on the MDHAQ which is calculated in 5 seconds, compared with almost 2 minutes for RA indices that require a formal joint count, such as DAS28 (disease activity score with 28-joint count) or CDAI (clinical disease activity index). MDHAQ with included RAPID3 scores appears as "scientific" as laboratory tests, formal joint counts, and indices such as DAS28 and CDAI, to assess patient status using standard, protocolized, quantitative measurement. MDHAQ/RAPID3 helps the patient prepare for the visit, enhances doctor-patient communication, and saves time for the physician. MDHAQ/RAPID3 is useful in all rheumatic diseases, and can be incorporated into routine clinical care with minimal extra work for physicians and staff. MDHAQ in no way prevents collection of formal joint counts, radiographs and other imaging studies, laboratory tests, or any other information regarded as important by a rheumatologist. MDHAQ provides quantitative, "scientific" data, rather than gestalt impressions, regarding patient status, change in status, prognosis, and outcomes of RA and all rheumatic diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25163735     DOI: 10.2174/1381612820666140825124544

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

Review 1.  [Treat to target and personalized medicine (precision medicine)].

Authors:  J Detert; G R Burmester
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

2.  The effect of concomitant hand osteoarthritis on pain and disease activity in patients with rheumatoid arthritis.

Authors:  Emmanuel Ruiz-Medrano; Hector Fabricio Espinosa-Ortega; Cesar Alejandro Arce-Salinas
Journal:  Clin Rheumatol       Date:  2019-05-10       Impact factor: 2.980

3.  Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis.

Authors:  Michael M Ward; Isabel Castrejon; Martin J Bergman; Maria I Alba; Lori C Guthrie; Theodore Pincus
Journal:  J Rheumatol       Date:  2018-10-15       Impact factor: 4.666

4.  Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis.

Authors:  Isabel Castrejón; Theodore Pincus; Daniel Wendling; Maxime Dougados
Journal:  RMD Open       Date:  2016-07-07

5.  Fibromyalgia Assessment Screening Tools (FAST) Based on Only Multidimensional Health Assessment Questionnaire (MDHAQ) Scores as Clues to Fibromyalgia.

Authors:  Juan Schmukler; Shakeel Jamal; Isabel Castrejon; Joel A Block; Theodore Pincus
Journal:  ACR Open Rheumatol       Date:  2019-08-22

6.  Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumatoid Arthritis.

Authors:  Xavier Janssens; Saskia Decuman; Filip De Keyser
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.